Allergan, a global pharmaceutical company, completed the acquisition of Chase Pharmaceuticals, a clinical-stage biopharmaceutical company, from Cipla Ventures for $125m. "We at Chase Pharmaceuticals are passionate about developing and bringing to physicians and their patients profoundly improved Alzheimer's disease treatments. I am very excited that Allergan has recognized the strong clinical value of our development programs and look forward to seeing Allergan apply its leading clinical development and regulatory expertise to bring these potential treatments forward for patients," Douglas Ingram, Chase Pharmaceuticals CEO.